United Kingdom

Psioxus Therapeutics

www.psioxus.com/
United Kingdom
SEARCH FILTERS
Time filter
Source Type

Patent
Psioxus Therapeutics | Date: 2017-07-05

A Process for the Production of Adenovirus The present disclosure relates to a continuous process for the manufacture of an adenovirus wherein the process comprises the steps: A) continuously culturing, in a vessel, mammalian cells infected with the adenovirus in the presence of media suitable for supporting the cells such that the virus replicates, wherein the cells are capable of supporting viral replication, and B) isolating from the media the virus produced from step a) wherein the isolation of virus is not subsequent to a cell lysis step, wherein viable cells for virus infection and production are maintained in the vessel at a level suitable for replicating the virus for the period of continuous manufacture, wherein the process comprises at least one media change or addition and at least one cell change or addition. The disclosure also extends to viruses populations obtained or obtainable from the method.


Patent
Psioxus Therapeutics | Date: 2016-08-08

The present disclosure provides a replication competent oncolytic adenovirus with selectivity for cancer cells, wherein the adenovirus comprises a transgene under the control of a promoter endogenous to the virus, wherein the transgene comprises a DNA sequence encoding a B7 protein or an active fragment thereof, compositions comprising same, methods of generating the viruses, and use of the viruses and compositions in treatment, particularly in the treatment of cancer.


Patent
Psioxus Therapeutics | Date: 2015-02-27

The present disclosure relates to a process for the manufacture of adenovirus having a fibre and hexon of subgroup B (such as Ad11, in particular Ad11p also known as the Slobitski strain) wherein the E4 region completely present or completely deleted said process comprises the steps: a. culturing mammalian cells infected with the adenovirus in the presence of media suitable for supporting the cells such that the virus replicates, wherein the cells are capable of supporting viral replication, and b. at the end of the culturing period isolating from the media the virus from step a) by filtering wherein the isolation of virus is not subsequent to a cell lysis step. The disclosure also extends to formulations and viruses obtained from the process.


Patent
Psioxus Therapeutics | Date: 2015-04-13

The present disclosure relates to a type B adenovirus wherein E4orf4 is deleted or non-functional and generally having a DNA sequence in the E3 region, in particular viruses of formula (I), compositions containing the virus, for example pharmaceutical formulations of the virus, processes for making the viruses and the compositions and use of any one of the same in treatment, particularly in the treatment of cancer, such as colorectal cancer and ovarian cancer. 5ITR-B_(1)-B_(A)-B_(2)-B_(X)-B_(B)-B_(T)-B_(3)-3ITR (I)


Patent
Psioxus Therapeutics | Date: 2017-01-04

The present disclosure relates to a process for the manufacture of adenovirus having a fibre and hexon of subgroup B (such as Ad11, in particular Ad11p also known as the Slobitski strain) wherein the E4 region completely present or completely deleted said process comprises the steps: a. culturing mammalian cells infected with the adenovirus in the presence of media suitable for supporting the cells such that the virus replicates, wherein the cells are capable of supporting viral replication, and b. at the end of the culturing period isolating from the media the virus from step a) by filtering wherein the isolation of virus is not subsequent to a cell lysis step. The disclosure also extends to formulations and viruses obtained from the process.


Patent
Psioxus Therapeutics | Date: 2017-02-22

The present disclosure relates to a type B adenovirus wherein E4orf4 is deleted or non-functional and generally having a DNA sequence in the E3 region, in particular viruses of formula (I), compositions containing the virus, for example pharmaceutical formulations of the virus, processes for making the viruses and the compositions and use of any one of the same in treatment, particularly in the treatment of cancer, such as colorectal cancer and ovarian cancer.


Patent
Psioxus Therapeutics | Date: 2016-10-21

The present invention provides an adjuvant-polymer construct comprising a polymer backbone which is covalently linked to 3 or more adjuvants, wherein the 3 or more adjuvants are each present in a pendant side chain, the adjuvants being connected to the polymer backbone either directly or via a spacer group.


Patent
Psioxus Therapeutics | Date: 2014-12-23

The present disclosure relates to a method of making an adenovirus plasmid comprising a part or all of an adenovirus genome and one or more original restriction sites allowing rapid and flexible manipulation of the adenovirus genome, and methods of preparing adenovirus constructs, for example comprising a transgene. The disclosure also extends to novel intermediates employed in and generated by the method, to plasmids and shuttle vectors of the method and to adenoviruses or adenoviral vectors obtainable from the plasmid and/or method. The disclosure further relates to use of the viruses or vectors, for example obtained from a method disclosed herein, in therapy, such as use in the treatment of cancer.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 1.73M | Year: 2013

ColoAd1 is a chimeric adenovirus serotype 3/11p, with a number of key characteristics that may make it a suitable oncolytic agent for the potential treatment of metastatic carcinomas. This is a phase I/IIa study designed to determine the safety, toxicity and tolerability of ColoAd1 and the clinical benefit and potential efficacy of ColoAd1 as a single agent and in combination with chemotherapy in women with recurrent platinum resistant ovarian cancer when administered intraperitoneally. Safety evaluations will be will be assessed using NCI CTCAE v4 and efficacy evaluations will be assessed using CT and [18F]-FDG PET/CT scans. A number of pharmacogenomics and biomarker assessments will also be performed.


Patent
Psioxus Therapeutics | Date: 2014-06-12

The present disclosure provides a method of treating a human patient comprising the steps of: systemically administering multiple doses of a parenteral formulation of a replication capable oncolytic adenovirus of subgroup B in a single treatment cycle, wherein the total dose given in each dose is in the range of 110^(10 )to 110^(14 )viral particles, and wherein each dose of virus is administered over a period of 1 to 90 minutes, for example at a rate of viral particle delivery in the range of 210^(10 )particles per minute to 210^(12 )particles per minute. The disclosure further extends to formulations of the said oncolytic adenoviruses and combination therapies of the viruses and formulations with other therapeutic agents.

Loading Psioxus Therapeutics collaborators
Loading Psioxus Therapeutics collaborators